Biotech Currents

Company on track to be fast follower in Friedreich’s ataxia

FDA slaps down Regeneron’s (REGN) odronextamab again

Company seeks to turn around treatment of congenital hyperinsulinism

Company seeks to boost oncology franchise with approval of treatment for follicular lymphoma

Bids for Verona (VRNA), Monogram (MGRM) may signal new life for M&A

After brief delay, FDA approves KalVista’s (KALV) sebetralstat as on-demand HAE treatment

New Data Could Redefine the Market for a Vision Disorder Treatment Company on the Verge of FDA Approval

Clinical trial data from Ascendis (ASND), Tourmaline (TRML) push stocks higher

aTyr Pharma's (ATYR) efzofitimod aims to get in front of pulmonary sarcoidosis, lung disease

IDEAYA's (IDYA) darovasertib to address uveal melanoma at various stages of disease

The Friday Biotech Perspective #41

ORR from Merus N.V.’s (NASDAQ:MRUS) H&N cancer drug triggers stock surge